| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
| ln Vitro |
Over a broad dose range, BAM 15 can raise O2 consumption without raising ROS. The cellular O2 consumption rate (OCR) was found to be increased by BAM 15 at low doses (100 nM to 1 μM) in a manner similar to that of FCCP, despite the structural differences between the two compounds. However, BAM 15 was also able to sustain high rates of uncoupled respiration in a variety of cell lines at higher concentrations (1 μM to 50 μM). BAM 15 was able to increase mitochondrial respiration in myoblasts and hepatocytes in the presence of oligomycin, and it was able to do so across a wider concentration range than FCCP. Mitochondrial enlargement caused by BAM 15 indicates that it is a protonophore. When supplied at concentrations up to 50 μM, BAM15-treated cells were more viable than FCCP-treated cells [1].
|
|---|---|
| ln Vivo |
In mice administered BAM 15, there was protection against renal damage compared to those treated with a vehicle. Additionally, 24 and 48 hours after ischemia, the animals' plasma creatinine levels were lower, there was less obstruction and immune cell infiltration, less tubular necrosis, and less brush border villus depletion.
|
| References |
| Molecular Formula |
C16H10F2N6O
|
|---|---|
| Molecular Weight |
340.29
|
| Exact Mass |
340.088
|
| CAS # |
210302-17-3
|
| PubChem CID |
565708
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
421.7±55.0 °C at 760 mmHg
|
| Flash Point |
208.9±31.5 °C
|
| Vapour Pressure |
0.0±1.0 mmHg at 25°C
|
| Index of Refraction |
1.728
|
| LogP |
4.19
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
25
|
| Complexity |
409
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
OEGJBRZAJRPPHL-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H10F2N6O/c17-9-5-1-3-7-11(9)19-13-14(20-12-8-4-2-6-10(12)18)22-16-15(21-13)23-25-24-16/h1-8H,(H,19,21,23)(H,20,22,24)
|
| Chemical Name |
5-N,6-N-bis(2-fluorophenyl)-[1,2,5]oxadiazolo[3,4-b]pyrazine-5,6-diamine
|
| Synonyms |
BAM-15 BAM 15 BAM15
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~146.93 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.35 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9387 mL | 14.6933 mL | 29.3867 mL | |
| 5 mM | 0.5877 mL | 2.9387 mL | 5.8773 mL | |
| 10 mM | 0.2939 mL | 1.4693 mL | 2.9387 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT04634409 | COMPLETEDWITH RESULTS | Drug: Bamlanivimab Drug: Etesevimab Drug: Placebo |
COVID-19 | Eli Lilly and Company | 2020-10-29 | Phase 2 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
